Retour
Fourchette du Jour
478,03 €
489,00 €
Fourchette 52 Semaines
425,00 €
603,88 €
Volume
1 500 865
Moyenne 50J / 200J
505,85 €
/
509,44 €
Clôture Précédente
477,97 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (626 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 59,4 | 0,4 |
| P/B | 9,5 | 2,9 |
| ROE % | 16,7 | 3,8 |
| Net Margin % | 28,4 | 3,9 |
| Rev Growth 5Y % | 15,2 | 10,0 |
| D/E | 0,0 | 0,2 |
Objectif de Cours des Analystes
Hold
638,75 €
+33.6%
Low: 550,00 €
High: 750,00 €
P/E Prévisionnel
47,6
BPA Prévisionnel
10,05 €
Croissance BPA (est.)
+0,0%
CA Est.
12 B
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2030 |
16,55 €
15,60 € – 17,75 €
|
19 B | 5 |
| FY2029 |
15,13 €
14,26 € – 16,23 €
|
17 B | 2 |
| FY2028 |
13,22 €
12,29 € – 14,32 €
|
15 B | 7 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 28, 2026 |
Samath Jamie
EVP & CFO & Enterprise Technol
|
other | 28 766 | — | — |
| Jan 29, 2026 |
Leonard Keith R
Director
|
other | 369 | — | — |
| Dec 15, 2025 |
Brosius Mark
See Remarks
|
sell | 464 | 548,49 € | 254 499 € |
| Dec 12, 2025 |
Brosius Mark
See Remarks
|
sell | 312 | 547,36 € | 170 776 € |
| Dec 10, 2025 |
Curet Myriam
EVP & Chief Medical Officer
|
other | 208 | 229,39 € | — |
| Dec 10, 2025 |
Curet Myriam
EVP & Chief Medical Officer
|
sell | 104 | 559,90 € | 58 230 € |
| Nov 12, 2025 |
BARRATT CRAIG H
Director
|
other | 1 500 | 71,32 € | — |
| Nov 12, 2025 |
BARRATT CRAIG H
Director
|
sell | 750 | 580,00 € | 435 000 € |
| Nov 12, 2025 |
Leonard Keith R
Director
|
other | 1 606 | — | — |
| Sep 4, 2025 |
Ladd Amy L
Director
|
sell | 335 | 440,69 € | 147 631 € |
| Sep 3, 2025 |
Ladd Amy L
Director
|
sell | 336 | 470,11 € | 157 957 € |
| Jun 4, 2025 |
Rosa David J.
President
|
other | 851 | — | — |
| May 16, 2025 |
Brosius Mark
SVP & Chief Mfg and Supply Cha
|
sell | 20 | 563,81 € | 11 276 € |
| May 15, 2025 |
Brosius Mark
SVP & Chief Mfg and Supply Cha
|
sell | 22 | 560,00 € | 12 320 € |
| May 14, 2025 |
Brosius Mark
SVP & Chief Mfg and Supply Cha
|
sell | 22 | 563,00 € | 12 386 € |
| May 13, 2025 |
Brosius Mark
SVP & Chief Mfg and Supply Cha
|
sell | 22 | 561,67 € | 12 357 € |
| May 12, 2025 |
Brosius Mark
SVP & Chief Mfg and Supply Cha
|
sell | 22 | 551,97 € | 12 143 € |
| May 1, 2025 |
Leonard Keith R
Director
|
grant | 531 | — | — |
| May 1, 2025 |
NACHTSHEIM JAMI K
Director
|
other | 4 800 | 90,49 € | — |
| May 1, 2025 |
NACHTSHEIM JAMI K
Director
|
sell | 2 400 | 520,00 € | 1 248 000 € |
Points Clés
Revenue grew 15,22% annually over 5 years — strong growth
Earnings grew 22,97% over the past year
ROE of 16,67% — decent returns on equity
Net margin of 28,38% shows strong profitability
Debt/Equity of 0,02 — conservative balance sheet
Generating 2,49B in free cash flow
Croissance
Revenue Growth (5Y)
15,22%
Revenue (1Y)20,51%
Earnings (1Y)22,97%
FCF Growth (3Y)82,28%
Qualité
Return on Equity
16,67%
ROIC12,19%
Net Margin28,38%
Op. Margin29,27%
Sécurité
Debt / Equity
0,02
Current Ratio4,87
Interest Coverage0,00
Valorisation
P/E Ratio
59,44
P/B Ratio9,52
EV/EBITDA56,60
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 20,51% | Revenue Growth (3Y) | 18,86% |
| Earnings Growth (1Y) | 22,97% | Earnings Growth (3Y) | 26,03% |
| Revenue Growth (5Y) | 15,22% | Earnings Growth (5Y) | 13,77% |
| Profitability | |||
| Revenue (TTM) | 10,06B | Net Income (TTM) | 2,86B |
| ROE | 16,67% | ROA | 13,84% |
| Gross Margin | 66,00% | Operating Margin | 29,27% |
| Net Margin | 28,38% | Free Cash Flow (TTM) | 2,49B |
| ROIC | 12,19% | FCF Growth (3Y) | 82,28% |
| Safety | |||
| Debt / Equity | 0,02 | Current Ratio | 4,87 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 59,44 | P/B Ratio | 9,52 |
| P/S Ratio | 16,87 | PEG Ratio | 3,17 |
| EV/EBITDA | 56,60 | Dividend Yield | 0,00% |
| Market Cap | 169,77B | Enterprise Value | 166,70B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10,06B | 8,35B | 7,12B | 6,22B | 5,71B |
| Net Income | 2,86B | 2,32B | 1,80B | 1,32B | 1,70B |
| EPS (Diluted) | 7,87 | 6,42 | 5,03 | 3,65 | 4,66 |
| Gross Profit | 6,64B | 5,63B | 4,73B | 4,20B | 3,96B |
| Operating Income | 2,95B | 2,35B | 1,77B | 1,58B | 1,82B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 20,63B | 18,84B | 15,44B | 12,97B | 13,56B |
| Total Liabilities | 2,69B | 2,31B | 2,04B | 1,86B | 1,60B |
| Shareholders' Equity | 17,82B | 16,43B | 13,31B | 11,04B | 11,95B |
| Total Debt | 302,80M | 146,00M | 0,0 | 0,0 | 87,00M |
| Cash & Equivalents | 3,37B | 2,03B | 2,75B | 1,58B | 1,29B |
| Current Assets | 9,78B | 7,11B | 7,89B | 6,25B | 5,84B |
| Current Liabilities | 2,01B | 1,75B | 1,66B | 1,42B | 1,15B |